《新股消息》科濟藥業(02171.HK)公開發售超購逾433倍及上限定價 一手中籤率僅5%
內地生物製藥公司科濟藥業(02171.HK)公布招股結果,發售價定於32.8元,為上限定價(每股招股價介乎29.6至32.8元),在港公開發售錄超購433.57倍,經重新分配後,公開發售股數增至全球發售股份總數的50%;每手500股,中籤率為5%。該股將於明日(18日)上市,聯席保薦人為高盛及瑞銀。
公司是次招股共引入9名基石投資者,包括禮來亞洲基金、新華人壽、CloudAlpha、睿遠、WT基金、廣發証券、Dymon Asia、常春藤及南方基金,合共4,732.2萬股發售股份,佔緊隨全球發售完成後公司已發行股本總額的約8.34%。
公司預計集資淨額為29.4億元,當中30%將用於為進一步開發核心候選產品BCMA CAR-T (CT053)提供資金;31%將用於為正在進行及已籌劃的其他管線候選產品的研發活動提供資金;20%將用於培養全面的製造及商業化能力;10%將用於繼續升級CAR-T技術及為早期研發活動提供資金;餘下9%將用於營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.